147 related articles for article (PubMed ID: 23117003)
21. Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies.
Escudier B; Osanto S; Ljungberg B; Porta C; Wagstaff J; Mulders P; Gore M; Bex A; Bellmunt J; Bracarda S; Franklin A; Honoré PH; Ravaud A; Steijn Jv; Aziz Z; Akaza H
Cancer Treat Rev; 2012 Apr; 38(2):127-32. PubMed ID: 21689888
[TBL] [Abstract][Full Text] [Related]
22. Locally advanced breast cancer: treatment guideline implementation with particular attention to low- and middle-income countries.
El Saghir NS; Eniu A; Carlson RW; Aziz Z; Vorobiof D; Hortobagyi GN;
Cancer; 2008 Oct; 113(8 Suppl):2315-24. PubMed ID: 18837023
[TBL] [Abstract][Full Text] [Related]
23. Optimising the management of choroidal neovascularisation in Asian patients: consensus on treatment recommendations for anti-VEGF therapy.
Koh A; Lim TH; Au Eong KG; Chee C; Ong SG; Tan N; Yeo I; Wong D
Singapore Med J; 2011 Apr; 52(4):232-40. PubMed ID: 21552782
[TBL] [Abstract][Full Text] [Related]
24. Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations.
Calvo E; Maroto P; del Muro XG; Climent MA; González-Larriba JL; Esteban E; López R; Paz-Ares L; Bellmunt J; Castellano D
Cancer Metastasis Rev; 2010 Aug; 29 Suppl 1():11-20. PubMed ID: 20640588
[TBL] [Abstract][Full Text] [Related]
25. Cancer prevention in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013.
Lertkhachonsuk AA; Yip CH; Khuhaprema T; Chen DS; Plummer M; Jee SH; Toi M; Wilailak S;
Lancet Oncol; 2013 Nov; 14(12):e497-507. PubMed ID: 24176569
[TBL] [Abstract][Full Text] [Related]
26. A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options.
Bellmunt J; Eisen T; Szczylik C; Mulders P; Porta C
BJU Int; 2011 Apr; 107(8):1190-9. PubMed ID: 21078050
[TBL] [Abstract][Full Text] [Related]
27. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
Motzer RJ; Jonasch E; Agarwal N; Bhayani S; Bro WP; Chang SS; Choueiri TK; Costello BA; Derweesh IH; Fishman M; Gallagher TH; Gore JL; Hancock SL; Harrison MR; Kim W; Kyriakopoulos C; LaGrange C; Lam ET; Lau C; Michaelson MD; Olencki T; Pierorazio PM; Plimack ER; Redman BG; Shuch B; Somer B; Sonpavde G; Sosman J; Dwyer M; Kumar R
J Natl Compr Canc Netw; 2017 Jun; 15(6):804-834. PubMed ID: 28596261
[TBL] [Abstract][Full Text] [Related]
28. Genitourinary imaging: part 2, role of imaging in medical management of advanced renal cell carcinoma.
Shinagare AB; Krajewski KM; Jagannathan JP; Ramaiya NH
AJR Am J Roentgenol; 2012 Nov; 199(5):W554-64. PubMed ID: 23096199
[TBL] [Abstract][Full Text] [Related]
29. Renal cell carcinoma: what the surgeon and treating physician need to know.
Chapin BF; Delacroix SE; Wood CG
AJR Am J Roentgenol; 2011 Jun; 196(6):1255-62. PubMed ID: 21606286
[TBL] [Abstract][Full Text] [Related]
30. Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma.
Calvo E; Maroto P; del Muro XG; Climent MA; González-Larriba JL; Esteban E; López R; Paz-Ares L; Bellmunt J; Castellano D
Cancer Metastasis Rev; 2010 Aug; 29 Suppl 1():1-10. PubMed ID: 20640589
[TBL] [Abstract][Full Text] [Related]
31. Current management of advanced and metastatic renal cell carcinoma.
Ather MH; Masood N; Siddiqui T
Urol J; 2010; 7(1):1-9. PubMed ID: 20209445
[TBL] [Abstract][Full Text] [Related]
32. [NCCN Asian consensus statement - can Asian patients with cancer accept treatment modalities from NCCN guidelines ?].
Ozono S; Hinotsu S; Namiki M; Akaza H
Gan To Kagaku Ryoho; 2014 Jun; 41(6):683-6. PubMed ID: 25129079
[TBL] [Abstract][Full Text] [Related]
33. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
Lam JS; Shvarts O; Leppert JT; Figlin RA; Belldegrun AS
J Urol; 2005 Jun; 173(6):1853-62. PubMed ID: 15879764
[TBL] [Abstract][Full Text] [Related]
34. Management of favorable-risk patients with metastatic renal cell carcinoma: when to start and when to stop targeted therapy.
Powles T; Albers P
Clin Genitourin Cancer; 2012 Dec; 10(4):213-8. PubMed ID: 22939100
[TBL] [Abstract][Full Text] [Related]
35. Delivering consensus from the Asian Oncology Summit 2009.
Collingridge D
Lancet Oncol; 2009 Nov; 10(11):1029-30. PubMed ID: 19880059
[No Abstract] [Full Text] [Related]
36. Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns.
Powles T
Clin Genitourin Cancer; 2012 Jun; 10(2):67-8. PubMed ID: 22608779
[No Abstract] [Full Text] [Related]
37. Renal cell carcinoma.
Garcia JA; Cowey CL; Godley PA
Curr Opin Oncol; 2009 May; 21(3):266-71. PubMed ID: 19339887
[TBL] [Abstract][Full Text] [Related]
38. [Clinical recommendations for treating and monitoring patients with renal cancer].
Petković M; Vrdoljak E; Ruzić IP; Belev B; Omrcen T; Ledina D; Tomek R; Ruzić B; Situm M; Buća A; Pisac VP;
Lijec Vjesn; 2012; 134(1-2):5-8. PubMed ID: 22519246
[TBL] [Abstract][Full Text] [Related]
39. Renal cell carcinoma: diagnosis, staging, and surveillance.
Ng CS; Wood CG; Silverman PM; Tannir NM; Tamboli P; Sandler CM
AJR Am J Roentgenol; 2008 Oct; 191(4):1220-32. PubMed ID: 18806169
[TBL] [Abstract][Full Text] [Related]
40. Conclusion and future directions.
Samlowski WE; Vogelzang NJ
Cancer J; 2008; 14(5):330-2. PubMed ID: 18836339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
